Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711009 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT00711009 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 206 participants.
The verdict
NCT00711009, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety, tolerability, and antiviral activity of the lopinavir/ritonavir tablet when administered in combination with reverse transcriptase inhibitors to lopinavir/ritonavir tablets when administered in combination with a human immunodeficiency virus type 1 ( HIV-1) integrase inhibitor in antiretroviral naive HIV-1 infected subjects.
Interventions
- DRUG lopinavir/ritonavir (LPV/r)
- DRUG emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
- DRUG raltegravir (RAL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711009
The ClinicalTrials.gov registry entry for NCT00711009 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which lopinavir/ritonavir (LPV/r) is the first listed.
NCT00711009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711009 about?
NCT00711009 is a clinical study titled "Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)". The purpose of this study is to compare the safety, tolerability, and antiviral activity of the lopinavir/ritonavir tablet when administered in combination with reverse transcriptase inhibitors to lopinavir/ritonavir tablets when administered in combination with a human immunodeficiency virus type 1...
What is the current status of trial NCT00711009?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2008-07. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00711009?
The interventions under investigation include: lopinavir/ritonavir (LPV/r) (DRUG), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (DRUG), raltegravir (RAL) (DRUG).
Who is sponsoring clinical trial NCT00711009?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.